Promis Neurosciences INC 8-K filings

ProMIS Neurosciences has announced a private placement financing that could yield up to $122.7 million to support the development of their Alzheimer's drug candidate, PMN310.

ProMIS Neurosciences reports positive top-line data from its Phase 1a clinical trial of PMN310, showing a favorable safety profile and dose-dependent levels of the antibody in cerebrospinal fluid.

ProMIS Neurosciences has been notified by Nasdaq that it does not meet the minimum market value requirement for continued listing.

ProMIS Neurosciences held its 2024 annual meeting, electing seven directors and approving the appointment of Baker Tilly US, LLP as its auditor.

ProMIS Neurosciences announced its first quarter 2024 financial results and provided an update on its clinical programs, including the Phase 1a trial of PMN310 for Alzheimer's disease.

ProMIS Neurosciences announced the publication of a study demonstrating that their antibody, PMN310, exhibits high selectivity for toxic amyloid-beta oligomers, potentially improving efficacy and reducing side effects in Alzheimer's treatment.

ProMIS Neurosciences announced its full year 2023 financial results and provided an update on its clinical programs, including the progress of its lead candidate PMN310 for Alzheimer's disease.